{"schema_version":"secwatch.filing_event.v1","accession":"0001753926-25-000842","form_type":"8-K","ticker":"LIPO","cik":"0001347242","company_name":"LIPELLA PHARMACEUTICALS INC.","filed_at":"2025-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.041467+00:00","generated_at":"2026-05-21T04:42:07.497693+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"confidence":"high","headline":"Lipella presents positive Phase 2a data for LP-310; 0.50mg dose shows stat-sig efficacy in OLP","bullets":["Statistically significant improvements at 0.50mg dose: IGA from 3.42 to 1.71 (p=0.007), REU from 26.91 to 11.88 (p=0.003).","OLP Symptom Severity Measure dropped from 14.92 to 4.88 (p=0.003); Pain NRS from 6.42 to 2.25 (p=0.003).","No treatment-related serious adverse events, no discontinuations, and no detectable systemic tacrolimus levels.","Data from 0.25mg and 0.50mg cohorts presented at 2025 AAOM/EAOM meeting; final topline data from fully enrolled trial expected Q2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001753926-25-000842","json":"https://secwatch.observer/filing/0001753926-25-000842.json","markdown":"https://secwatch.observer/filing/0001753926-25-000842.md","text":"https://secwatch.observer/filing/0001753926-25-000842.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1347242/000175392625000842/0001753926-25-000842-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1347242/000175392625000842/g084819_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T04:42:07.497693+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}